Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

Benzinga06-29

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

  • Wall Street expects Concentrix Corp. (NASDAQ:CNXC) to post quarterly earnings at $2.64 per share on revenue of $2.47 billion after the closing bell, according to data from Benzinga Pro. Concentrix shares jumped 11% to close at $25.00 on Friday.
  • Lantheus Holdings Inc. (NASDAQ:LNTH) announced that the FDA issued a Complete Response Letter regarding its new drug application for LNTH-2501. Lantheus shares rose 0.7% to close at $109.80 on Friday.
  • Analysts are expecting AeroVironment Inc. (NASDAQ:AVAV) to post quarterly earnings at $1.46 per share on revenue of $558.81 million. The company will release earnings after the markets close. AeroVironment shares gained 0.9% to close at $137.95 on Friday.

Check out our premarket coverage here

  • Viridian Therapeutics Inc. (NASDAQ:VRDN) announced the U.S. FDA approval and launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease. Viridian Therapeutics shares jumped 10.7% to $19.81 in the after-hours trading session.
  • Universe Pharmaceuticals Inc. (NASDAQ:UPC) disclosed that it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares gained 4.2% to close at $2.96 on Friday.

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment